38 results about "Translation initiation sites" patented technology

Compositions and methods are provided for the treatment and diagnosis of diseases amenable to treatment through modulation of the synthesis or metabolism of intercellular adhesion molecules. In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with nucleic acids encoding intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and endothelial leukocyte adhesion molecule-1. The oligonucleotide comprises nucleotide units sufficient in identity and number to effect said specific hybridization. In other preferred embodiments, the oligonucleotides are specifically hybridizable with a transcription initiation site, a translation initiation site, 5'-untranslated sequences, 3'-untranslated sequences, and intervening sequences. Methods of treating animals suffering from disease amenable to therapeutic intervention by modulating cell adhesion proteins with an oligonucleotide specifically hybridizable with RNA or DNA corresponding to one of the foregoing proteins are disclosed. Methods for treatment of diseases responding to inhibition of cell adhesion molecules are disclosed.

Staphylococcus aureus is notorious for developing resistance to virtually all antibiotics to which it is exposed. Staphylococcal phage 2638A endolysin is a peptidoglycan hydrolase that is lytic for S. aureus when exposed externally, making it a new antimicrobial candidate. It shares a common protein organization with over 40 other staphylococcal peptidoglycan hydrolases: a CHAP endopeptidase domain, a mid-protein amidase 2 domain and a C-terminal SH3b cell wall binding domain. It is the first phage endolysin reported with a cryptic translational start site between the CHAP and amidase domains. Deletion analysis indicates that the amidase domain confers most of the lytic activity and requires the full SH3b domain for maximal activity. It is common for one domain to demonstrate dominant activity over another; however, the phage 2638A endolysin is the first to show high amidase domain activity dominant over the N-terminal CHAP domain, an important finding for targeting novel peptidoglycan bonds.

The invention discloses a method for detecting ox FTO (Fat Mass and Obesity-associated) gene single nucleotide polymorphism (SNP), which comprises the following steps of: carrying out PCR (Polymerase Chain Reaction) amplification on an ox FTO gene by adopting FTO gene-contained ox whole genome DNA to be detected as a template and a primer pair P as a primer; after carrying out high-temperature denaturation on a PCR product, carrying out polyacrylamide gel electrophoresis; and identifying the SNP of the 783rd site (+1 as a translation initiation site) of an ox FTO gene coding area according toa polyacrylamide gel electrophoresis result. Because the FTO gene function involves in body length and body height characters, the detecting method provided by the invention lays the foundation for establishing an SNP and growth character relation of the FTO gene so as to be used for marker-assisted selection (MAS) of growth characters for Chinese beef and rapidly establish an ox population with favorable genetic resources.

Provided herein are methods of treating a cancer in a patient comprising administration of an effective amount of a nuclease-resistant polynucleotide that hybridizes to the translation initiation site of a Grb2 nucleic acid in the patient and either a Bcr-Abl tyrosine kinase inhibitor (e.g., dasatinib) or a cytidine analogue (e.g., decitabine or cytarabine). The cancer may be Ph+ and / or Bcr-Abl positive chronic myelogenous leukemia or acute myeloid leukemia or myelodysplastic syndrome.

Compositions and methods are provided for the treatment and diagnosis of diseases amenable to treatment through modulation of the synthesis or metabolism of intercellular adhesion molecules. In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with nucleic acids encoding intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and endothelial leukocyte adhesion molecule-1. The oligonucleotide comprises nucleotide units sufficient in identity and number to effect said specific hybridization. In other preferred embodiments, the oligonucleotides are specifically hybridizable with a transcription initiation site, a translation initiation site, 5'-untranslated sequences, 3'-untranslated sequences, and intervening sequences. Methods of treating animals suffering from disease amenable to therapeutic intervention by modulating cell adhesion proteins with an oligonucleotide specifically hybridizable with RNA or DNA corresponding to one of the foregoing proteins are disclosed. Methods for treatment of diseases responding to modulation cell adhesion molecules are disclosed.

The invention provides an N-terminal extended PTEN subtype PTENζ protein and its coding gene and application, belonging to the technical field of functional proteins. The PTEN subtype provided by the present invention is a 28aa polypeptide connected to the N-terminus on the basis of the PTEN protein, and the polypeptide is a Golgi localization signal peptide. Translation of PTENζ protein is initiated at a non-canonical AUG translation initiation site in the 5’‑UTR region‑ATT 948 , the palindromic structure downstream of this site plays an important role in translation initiation. by ATT 948 The protein with a sequence of 431 amino acids after initial translation was named PTENζ. PTENζ is mainly distributed in the Golgi apparatus and cell membrane. The present invention uses CRISPR-Cas9 to specifically knock out PTENζ in Hela cells, and uses the RUSH system to confirm that PTENζ-specific knockout leads to a significant increase in the transport speed of vesicles from the endoplasmic reticulum to the Golgi apparatus.

The present invention relates to the field of cancer. More specifically, the present invention provides methods and compositions related to certain promoter mutations in cancer. In one embodiment, a method for treating a subject having thyroid cancer comprises the steps of (a) obtaining a biological sample from the subject; (b) performing an assay on the sample obtained from the subject to identify a mutation at 1 295 228 C>T (C228T) and 1 295 250 C>T (C250T), corresponding to −124 C>T and −146 C>T from the translation start site in the promoter of the telomerase reverse transcriptase (TERT) gene; (c) identifying the subject as having or likely to develop aggressive thyroid cancer if the C228T and / or C250T mutation is identified; and (d) treating the subject with one or more treatment modalities appropriate for a subject having or likely to develop aggressive thyroid cancer.

The present invention is directed to the identification of a novel repressor located between ˜1.2 kb to ˜1.6 kb from the translation start site of the IFN-λ1 promoter. The present invention provides a method of using siRNAs against ZEB1 (binds to the repressor region) and BLIMP-1 (binds outside the repressor region) and increases the promoter activity of IFN-λ1 (i.e., increases the production of IFN-λ1 protein). siRNAs against ZEB1 mRNA or BLIMP-1 mRNA increase IFN-λ1 gene activity. There is provided a therapeutic application of siRNAs against ZEB1 and BLIMP-1 mRNAs in treating a mammal (including a human) by increasing the production of IFN-λ1 protein that promotes an anti-viral response as well as treats asthma diseases.

The invention relates to the technical field of transgenics, in particular to a DNA molecule, its application and a method for obtaining ramie plants with high root mass. In the DNA molecule, the 2000-2500 bp sequence upstream of the translation start site of the 5' end untranslated region of the ramie BnWOX8 gene is replaced by the sequence of SEQ ID NO: 1. The invention transfers the modified DNA molecule into the ramie plant, and the obtained ramie line shows higher production capacity of the root system, and has no significant influence on the total flavonoid content in the root system.